SG160424A1 - Compositions of influenza viral proteins and methods of use thereof - Google Patents

Compositions of influenza viral proteins and methods of use thereof

Info

Publication number
SG160424A1
SG160424A1 SG201001924-8A SG2010019248A SG160424A1 SG 160424 A1 SG160424 A1 SG 160424A1 SG 2010019248 A SG2010019248 A SG 2010019248A SG 160424 A1 SG160424 A1 SG 160424A1
Authority
SG
Singapore
Prior art keywords
compositions
methods
influenza viral
viral proteins
fusion proteins
Prior art date
Application number
SG201001924-8A
Other languages
English (en)
Inventor
Thomas J Powell
Valerian Nakaar
Langzhou Song
William F Mcdonald
Duane D Hewitt
Original Assignee
Vaxinnate Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaxinnate Corp filed Critical Vaxinnate Corp
Publication of SG160424A1 publication Critical patent/SG160424A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG201001924-8A 2004-12-21 2005-12-21 Compositions of influenza viral proteins and methods of use thereof SG160424A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US63835004P 2004-12-21 2004-12-21
US63825404P 2004-12-21 2004-12-21
US64506705P 2005-01-19 2005-01-19
US65320705P 2005-02-15 2005-02-15
US66687805P 2005-03-31 2005-03-31
US68207705P 2005-05-18 2005-05-18
US74120205P 2005-11-30 2005-11-30

Publications (1)

Publication Number Publication Date
SG160424A1 true SG160424A1 (en) 2010-04-29

Family

ID=36272492

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201001924-8A SG160424A1 (en) 2004-12-21 2005-12-21 Compositions of influenza viral proteins and methods of use thereof

Country Status (9)

Country Link
EP (1) EP1831259A2 (ja)
JP (1) JP2008524261A (ja)
AU (2) AU2005319141B8 (ja)
BR (1) BRPI0519705A2 (ja)
CA (1) CA2593746A1 (ja)
MX (1) MX2007007586A (ja)
NZ (1) NZ556004A (ja)
SG (1) SG160424A1 (ja)
WO (1) WO2006069262A2 (ja)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1841785A2 (en) * 2005-01-19 2007-10-10 Vaxinnate Corporation Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
EP2476432B1 (en) 2006-03-07 2015-08-19 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
EP2012829A4 (en) * 2006-04-24 2010-04-21 Protelix Inc PROCESS FOR PRODUCING VIRAL VACCINE AND THERAPEUTIC PEPTIDE ANTIGENS
DK2066339T3 (da) * 2006-09-18 2014-11-03 Univ Arkansas Sammensætninger og fremgangsmåder til forstærkning af immunreaktioner
EP1925318A1 (en) * 2006-11-20 2008-05-28 Paul-Ehrlich-Institut Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu
US8778847B2 (en) * 2007-06-13 2014-07-15 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Immunogenic peptides of influenza virus
MX2010001284A (es) 2007-08-02 2010-08-31 Biondvax Pharmaceuticals Ltd Vacunas contra la influenza con multiepitope multimerico.
GB0720250D0 (en) * 2007-10-17 2007-11-28 Univ Edinburgh Immunogenic compositions containing escherichia coli h7 flagella and methods of use thereof
US8470771B2 (en) 2007-11-14 2013-06-25 Institute Of Microbiology, Chinese Academy Of Sciences Method and medicament for inhibiting the infection of influenza virus
ES2594102T3 (es) 2008-04-18 2016-12-15 Vaxinnate Corporation Mutantes por deleción de la flagelina y métodos para su uso
WO2010115229A1 (en) 2009-04-09 2010-10-14 The University Of Melbourne Immunogenic composition and uses thereof
MX348663B (es) * 2009-09-08 2017-05-26 Inst Tecnologico Estudios Superiores Monterrey Proceso de producción de una vacuna recombinante, dicha vacuna expresable en cepas de escherichia coli y su uso para combatir la influenza a h1ni1 brote 2009.
AU2011203740B2 (en) * 2010-01-06 2014-11-13 Vaxinnate Corporation Methods and compositions for providing protective immunity in the elderly
ES2643646T3 (es) 2010-01-21 2017-11-23 The Board Of Trustees Of The University Of Arkansas Vectores de vacuna y métodos para potenciar las respuestas inmunitarias
EP2552490A4 (en) * 2010-03-26 2013-12-18 Emergent Product Dev Gaithersburg Inc INFLUENZA MATRIX 2 PROTEIN ECKTOMOMAS, EXPRESSION SYSTEM THEREFOR AND USES THEREOF
GB201009273D0 (en) * 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
DK2618842T3 (da) 2010-09-22 2019-07-01 Ena Therapeutics Pty Ltd Hidtil ukendt immunstimulerende fremgangsmåde
CN103517713A (zh) 2011-02-22 2014-01-15 彼昂德瓦克斯医药有限公司 在改善的季节性和大流行性流感疫苗中的多聚体多表位多肽
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
EP2914283B1 (en) * 2012-11-05 2020-05-20 Georgia State University Research Foundation, Inc. Universal influenza vaccine based on heterologous multiple m2e proteins
RU2571944C1 (ru) * 2014-10-17 2015-12-27 Общество с ограниченной ответственностью "НТфарма" Противогриппозная вакцина широкого спектра действия против птичьего гриппа а на основе эктодомена белка м2
EP3990428A4 (en) 2019-06-26 2023-07-19 ENA Respiratory Pty Ltd NOVEL MOLECULES
AU2022338350A1 (en) * 2021-09-02 2024-02-29 Ena Respiratory Pty Ltd Formulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101121754B (zh) * 2002-08-12 2012-02-29 昆士兰医学研究所理事会 含有辅助t细胞和b细胞表位的新的免疫原性脂肽
US20040223976A1 (en) * 2003-03-07 2004-11-11 Elisabetta Bianchi Influenza virus vaccine

Also Published As

Publication number Publication date
EP1831259A2 (en) 2007-09-12
MX2007007586A (es) 2007-12-10
BRPI0519705A2 (pt) 2009-03-10
AU2005319141A1 (en) 2006-06-29
AU2005319141B8 (en) 2010-03-18
NZ556004A (en) 2010-05-28
CA2593746A1 (en) 2006-06-29
AU2010200048A1 (en) 2010-01-28
WO2006069262A3 (en) 2007-02-01
WO2006069262A2 (en) 2006-06-29
JP2008524261A (ja) 2008-07-10
AU2005319141B2 (en) 2010-02-18

Similar Documents

Publication Publication Date Title
SG160424A1 (en) Compositions of influenza viral proteins and methods of use thereof
CY1119243T1 (el) Φαρμακοτεχνικες μορφες ανταγωνιστη του vegf
WO2003083058A3 (en) Replikin peptides in rapid replication of glioma cells and in influenza epidemics
WO2007053188A3 (en) Production of multivalent virus like particles
BRPI0507118A (pt) polipeptìdeos de interferon humano modificado e seus usos
WO2004084805A3 (en) Acetylated tat polypeptides and methods of use thereof
NZ521396A (en) Fusion proteins comprising two or more Neisseria polypeptides
DE60329983D1 (de) Wachsestersynthase-dna-sequenz, protein und verwendungen davon
ATE529442T1 (de) Verbesserte humane interferon-moleküle und ihre verwendungen
EA200801798A1 (ru) Виросомоподобные везикулы, содержащие антигены, производные от gp41
EP1615945A4 (en) GLYCOPEGYLATION METHOD AND PROTEINS / PEPTIDES PRODUCED THEREFROM
PL1699822T3 (pl) Białka fuzyjne IL-7 z częściami przeciwciała, ich otrzymywanie oraz ich zastosowanie
DE602005022056D1 (de) Polypeptidsequenzen, die an der modulation des immunsupppressiven effekts viraler proteine beteiligt sind
WO2003068941A3 (en) Modulation of immune response by non-peptide binding stress response polypeptides
WO2008134697A3 (en) Prrsv vaccins based on gp5 proteins
ATE389397T1 (de) Adjuvante zusammensetzungen
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
ATE439441T1 (de) Veränderte, fluoreszierende proteine
MY144766A (en) Plant virus coat fusion proteins with gdf8 epitopes and vaccines thereof
WO2001094949A3 (en) Soluble cd1 compositions and uses thereof
WO2005013904A3 (en) Sars nucleic acids, proteins, vaccines, and uses thereof
WO2006073422A3 (en) Activation of natural killer (nk) cells and methods of use
DK1578772T3 (da) Cytokiner og cytokinreceptorer med reduceret immunogenicitet
WO2006060557A3 (en) Protein arrays and methods and systems for producing the same
WO2001051512A3 (en) Human and parasite orphan receptor proteins